Reuters logo
4 months ago
BRIEF-Corvus Pharmaceuticals announces interim safety and efficacy results from its ongoing Phase 1/1B study of CPI-444
April 4, 2017 / 3:40 PM / 4 months ago

BRIEF-Corvus Pharmaceuticals announces interim safety and efficacy results from its ongoing Phase 1/1B study of CPI-444

1 Min Read

April 4 (Reuters) - Corvus Pharmaceuticals Inc:

* Corvus Pharmaceuticals announces interim results from ongoing Phase 1/1B study demonstrating safety and clinical activity of lead checkpoint inhibitor CPI-444 in patients with advanced cancers

* Trial data showed that treatment with CPI-444 as a single agent and in combination with atezolizumab was well tolerated

* Says CPI-444 has been well tolerated to date

* Of 37 patients who showed evidence of disease control, 23 remain on treatment Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below